Logo image of FENC

FENNEC PHARMACEUTICALS INC (FENC) Stock Fundamental Analysis

USA - NASDAQ:FENC - CA31447P1009 - Common Stock

8.99 USD
+0.03 (+0.33%)
Last: 10/24/2025, 8:23:36 PM
8.99 USD
0 (0%)
After Hours: 10/24/2025, 8:23:36 PM
Fundamental Rating

2

FENC gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. FENC has a bad profitability rating. Also its financial health evaluation is rather negative. FENC does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

FENC had negative earnings in the past year.
In the past year FENC has reported a negative cash flow from operations.
FENC had negative earnings in each of the past 5 years.
FENC had negative operating cash flow in 4 of the past 5 years.
FENC Yearly Net Income VS EBIT VS OCF VS FCFFENC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M

1.2 Ratios

The Return On Assets of FENC (-26.78%) is better than 71.16% of its industry peers.
Industry RankSector Rank
ROA -26.78%
ROE N/A
ROIC N/A
ROA(3y)-49.42%
ROA(5y)-56.66%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
FENC Yearly ROA, ROE, ROICFENC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 600 800

1.3 Margins

With an excellent Gross Margin value of 89.89%, FENC belongs to the best of the industry, outperforming 91.57% of the companies in the same industry.
FENC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 89.89%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
FENC Yearly Profit, Operating, Gross MarginsFENC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

3

2. Health

2.1 Basic Checks

Compared to 1 year ago, FENC has more shares outstanding
FENC has more shares outstanding than it did 5 years ago.
The debt/assets ratio for FENC has been reduced compared to a year ago.
FENC Yearly Shares OutstandingFENC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
FENC Yearly Total Debt VS Total AssetsFENC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -3.18, we must say that FENC is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -3.18, FENC perfoms like the industry average, outperforming 45.13% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -3.18
ROIC/WACCN/A
WACCN/A
FENC Yearly LT Debt VS Equity VS FCFFENC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

A Current Ratio of 4.88 indicates that FENC has no problem at all paying its short term obligations.
FENC's Current ratio of 4.88 is in line compared to the rest of the industry. FENC outperforms 52.62% of its industry peers.
FENC has a Quick Ratio of 4.61. This indicates that FENC is financially healthy and has no problem in meeting its short term obligations.
FENC has a Quick ratio of 4.61. This is comparable to the rest of the industry: FENC outperforms 52.43% of its industry peers.
Industry RankSector Rank
Current Ratio 4.88
Quick Ratio 4.61
FENC Yearly Current Assets VS Current LiabilitesFENC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

3

3. Growth

3.1 Past

FENC shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -520.00%.
Looking at the last year, FENC shows a very negative growth in Revenue. The Revenue has decreased by -31.89% in the last year.
EPS 1Y (TTM)-520%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45%
Revenue 1Y (TTM)-31.89%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%32.91%

3.2 Future

FENC is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 240523.00% yearly.
Based on estimates for the next years, FENC will show a very strong growth in Revenue. The Revenue will grow by 24.44% on average per year.
EPS Next Y-132665236383229020%
EPS Next 2Y10894974643.37%
EPS Next 3Y26121300%
EPS Next 5Y240523%
Revenue Next Year-21.01%
Revenue Next 2Y14.09%
Revenue Next 3Y15.4%
Revenue Next 5Y24.44%

3.3 Evolution

FENC Yearly Revenue VS EstimatesFENC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M
FENC Yearly EPS VS EstimatesFENC Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 4

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for FENC. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 13.64, the valuation of FENC can be described as correct.
FENC's Price/Forward Earnings ratio is rather cheap when compared to the industry. FENC is cheaper than 95.88% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.92. FENC is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 13.64
FENC Price Earnings VS Forward Price EarningsFENC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FENC Per share dataFENC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1

4.3 Compensation for Growth

A more expensive valuation may be justified as FENC's earnings are expected to grow with 26121300.00% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10894974643.37%
EPS Next 3Y26121300%

More info and screens

0

5. Dividend

5.1 Amount

FENC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FENNEC PHARMACEUTICALS INC

NASDAQ:FENC (10/24/2025, 8:23:36 PM)

After market: 8.99 0 (0%)

8.99

+0.03 (+0.33%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14 2025-08-14/bmo
Earnings (Next)11-06 2025-11-06/bmo
Inst Owners56.74%
Inst Owner Change0%
Ins Owners2.21%
Ins Owner Change0.84%
Market Cap250.19M
Revenue(TTM)33.30M
Net Income(TTM)-12050000
Analysts85.45
Price Target14.08 (56.62%)
Short Float %5.7%
Short Ratio17.73
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-71.86%
Min EPS beat(2)-199.56%
Max EPS beat(2)55.84%
EPS beat(4)1
Avg EPS beat(4)-101.98%
Min EPS beat(4)-199.56%
Max EPS beat(4)55.84%
EPS beat(8)3
Avg EPS beat(8)-153.59%
EPS beat(12)4
Avg EPS beat(12)-110.94%
EPS beat(16)6
Avg EPS beat(16)-92.6%
Revenue beat(2)1
Avg Revenue beat(2)2.15%
Min Revenue beat(2)-0.57%
Max Revenue beat(2)4.87%
Revenue beat(4)1
Avg Revenue beat(4)-18.28%
Min Revenue beat(4)-53.52%
Max Revenue beat(4)4.87%
Revenue beat(8)4
Avg Revenue beat(8)-6.65%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)7.81%
EPS NQ rev (1m)-130.57%
EPS NQ rev (3m)-121.4%
EPS NY rev (1m)-278.71%
EPS NY rev (3m)-142.98%
Revenue NQ rev (1m)-16.19%
Revenue NQ rev (3m)-15.51%
Revenue NY rev (1m)-4.68%
Revenue NY rev (3m)-5.31%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 13.64
P/S 7.51
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.42
EYN/A
EPS(NY)0.66
Fwd EY7.33%
FCF(TTM)-0.43
FCFYN/A
OCF(TTM)-0.43
OCFYN/A
SpS1.2
BVpS-0.25
TBVpS-0.25
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -26.78%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 89.89%
FCFM N/A
ROA(3y)-49.42%
ROA(5y)-56.66%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.74
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.88
Quick Ratio 4.61
Altman-Z -3.18
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-520%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45%
EPS Next Y-132665236383229020%
EPS Next 2Y10894974643.37%
EPS Next 3Y26121300%
EPS Next 5Y240523%
Revenue 1Y (TTM)-31.89%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%32.91%
Revenue Next Year-21.01%
Revenue Next 2Y14.09%
Revenue Next 3Y15.4%
Revenue Next 5Y24.44%
EBIT growth 1Y-257.95%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year2497.85%
EBIT Next 3Y306.35%
EBIT Next 5YN/A
FCF growth 1Y43.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y43.74%
OCF growth 3YN/A
OCF growth 5YN/A

FENNEC PHARMACEUTICALS INC / FENC FAQ

What is the ChartMill fundamental rating of FENNEC PHARMACEUTICALS INC (FENC) stock?

ChartMill assigns a fundamental rating of 2 / 10 to FENC.


What is the valuation status for FENC stock?

ChartMill assigns a valuation rating of 4 / 10 to FENNEC PHARMACEUTICALS INC (FENC). This can be considered as Fairly Valued.


How profitable is FENNEC PHARMACEUTICALS INC (FENC) stock?

FENNEC PHARMACEUTICALS INC (FENC) has a profitability rating of 1 / 10.


How financially healthy is FENNEC PHARMACEUTICALS INC?

The financial health rating of FENNEC PHARMACEUTICALS INC (FENC) is 3 / 10.